Tag Archives: miRagen Therapeutics Inc

Miragen Therapeutics Inc (MGEN) Receives a Buy from Oppenheimer

In a report released today, Leah R. Cann from Oppenheimer maintained a Buy rating on Miragen Therapeutics Inc (MGEN – Research Report), with a price target of $19. The company’s shares opened today at $3.53. Cann observed: “The data presented

Oppenheimer Thinks Miragen Therapeutics Inc’s Stock is Going to Recover

In a report released yesterday, Leah R. Cann from Oppenheimer maintained a Buy rating on Miragen Therapeutics Inc (MGEN – Research Report), with a price target of $19. The company’s shares closed yesterday at $4.37, close to its 52-week low

Analysts Offer Insights on Healthcare Companies: Miragen Therapeutics Inc (NASDAQ: MGEN) and Momenta Pharma (NASDAQ: MNTA)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Miragen Therapeutics Inc (NASDAQ:MGEN) and Momenta Pharma (NASDAQ:MNTA). Miragen Therapeutics Inc (MGEN) Oppenheimer analyst Leah R. Cann maintained a Buy rating on Miragen

Wedbush Thinks Miragen Therapeutics Inc’s Stock is Going to Recover

Wedbush analyst Liana Moussatos reiterated a Buy rating on Miragen Therapeutics Inc (NASDAQ: MGEN) today and set a price target of $19. The company’s shares closed yesterday at $6.29, close to its 52-week low of $5.01. According to TipRanks.com, Moussatos

Analysts Offer Insights on Healthcare Companies: Miragen Therapeutics Inc (NASDAQ: MGEN) and Bluebird Bio (NASDAQ: BLUE)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Miragen Therapeutics Inc (NASDAQ:MGEN) and Bluebird Bio (NASDAQ:BLUE). Miragen Therapeutics Inc (MGEN) Oppenheimer analyst Leah R. Cann maintained a Buy rating on Miragen Therapeutics Inc

Oppenheimer Sticks to Its Buy Rating for Miragen Therapeutics Inc

Oppenheimer analyst Leah R. Cann maintained a Buy rating on Miragen Therapeutics Inc (NASDAQ: MGEN) yesterday and set a price target of $19. The company’s shares closed on Friday at $7.32. Cann noted: “We cover miRagen Therapeutics with an Outperform